Literature DB >> 35341315

Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.

T A Alsenani1, S L Viviani1, V Kumar1, M A Taracila2,3, C R Bethel2, M D Barnes2, K M Papp-Wallace2, R K Shields4, M H Nguyen4, C J Clancy4,5, R A Bonomo1,2,3,6,7,8,9, F van den Akker1.   

Abstract

Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) present a global clinical threat, as these β-lactamases confer resistance to carbapenems and oxyimino-cephalosporins. Recent clinically identified KPC variants with substitutions at Ambler position D179, located in the Ω loop, are resistant to the β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam, but susceptible to meropenem-vaborbactam. To gain insights into ceftazidime-avibactam resistance conferred by D179N/Y variants of KPC-2, crystal structures of these variants were determined. The D179N KPC-2 structure revealed that the change of the carboxyl to an amide moiety at position 179 disrupted the salt bridge with R164 present in wild-type KPC-2. Additional interactions were disrupted in the Ω loop, causing a decrease in the melting temperature. Shifts originating from N179 were also transmitted toward the active site, including ∼1-Å shifts of the deacylation water and interacting residue N170. The structure of the D179Y KPC-2 β-lactamase revealed more drastic changes, as this variant exhibited disorder of the Ω loop, with other flanking regions also being disordered. We postulate that the KPC-2 variants can accommodate ceftazidime because the Ω loop is displaced in D179Y or can be more readily displaced in D179N KPC-2. To understand why the β-lactamase inhibitor vaborbactam is less affected by the D179 variants than avibactam, we determined the crystal structure of D179N KPC-2 in complex with vaborbactam, which revealed wild-type KPC-2-like vaborbactam-active site interactions. Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Ω loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.

Entities:  

Keywords:  antibiotic resistance; beta-lactamase; protein crystallography

Mesh:

Substances:

Year:  2022        PMID: 35341315      PMCID: PMC9017313          DOI: 10.1128/aac.02414-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  73 in total

1.  Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.

Authors:  Stephan Göttig; Denia Frank; Eleonora Mungo; Anika Nolte; Michael Hogardt; Silke Besier; Thomas A Wichelhaus
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

2.  XDS.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

3.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 4.  Phosphorylation and dephosphorylation of histidine residues in proteins.

Authors:  Susanne Klumpp; Josef Krieglstein
Journal:  Eur J Biochem       Date:  2002-02

5.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

6.  Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases.

Authors:  Wei Ke; Christopher R Bethel; Jodi M Thomson; Robert A Bonomo; Focco van den Akker
Journal:  Biochemistry       Date:  2007-04-19       Impact factor: 3.162

Review 7.  Interplay between β-lactamases and new β-lactamase inhibitors.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Nat Rev Microbiol       Date:  2019-05       Impact factor: 60.633

8.  Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam.

Authors:  Carolina Venditti; Carla Nisii; Milva Ballardini; Marcello Meledandri; Antonino Di Caro
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

9.  Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.

Authors:  Malligarjunan Rajavel; Vijay Kumar; Ha Nguyen; Jacob Wyatt; Steven H Marshall; Krisztina M Papp-Wallace; Prasad Deshpande; Satish Bhavsar; Ravindra Yeole; Sachin Bhagwat; Mahesh Patel; Robert A Bonomo; Focco van den Akker
Journal:  mBio       Date:  2021-02-16       Impact factor: 7.867

Review 10.  The Role of the Ω-Loop in Regulation of the Catalytic Activity of TEM-Type β-Lactamases.

Authors:  Alexey Egorov; Maya Rubtsova; Vitaly Grigorenko; Igor Uporov; Alexander Veselovsky
Journal:  Biomolecules       Date:  2019-12-11
View more
  1 in total

Review 1.  Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.

Authors:  Claire Amaris Hobson; Gautier Pierrat; Olivier Tenaillon; Stéphane Bonacorsi; Béatrice Bercot; Ella Jaouen; Hervé Jacquier; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2022-08-18       Impact factor: 5.938

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.